Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2020-06-01
|
| Серія: | Frontiers in Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/article/10.3389/fonc.2020.00694/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|